8-K 1 pa79298.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - - - - - - - - - - - FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 29, 2002 Date of Report (Date of Earliest Event Reported) GENELABS TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter) 0-19222 94-3010150 (Commission File Number) (IRS Employer Identification No.) 505 Penobscot Drive Redwood City, California 94063 (Address of Principal Executive Offices) (Zip Code) (650) 369-9500 (Registrant's Telephone Number, including Area Code) Item 5. Other Events On August 29, 2002, Genelabs Technologies, Inc. ("Genelabs") issued a press release that the U.S. Food and Drug Administration issued an approvable letter on August 28, 2002 for Genelabs' New Drug Application for Prestara(TM), formerly known as Aslera(TM) or GL701. Item 7. Exhibits EXHIBIT NO. DESCRIPTION 99.1 Press Release dated August 29, 2002. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized. Dated: August 30, 2002 GENELABS TECHNOLOGIES, INC. By: /s/ Heather Criss Keller ------------------------------ Name: Heather Criss Keller Title: Vice President, General Counsel EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release dated August 29, 2002.